Cold urticaria: what to do when omalizumab does not achieve complete symptom control
Clinical scenario
This protocol is for patients with cold urticaria who are already on a 2nd generation H1-antihistamine plus omalizumab but have not reached sustained, complete symptom control — defined as a continuous Urticaria Activity Score over 7 days (UAS7) of zero and a well-controlled disease state.
Previous treatment — insufficient response
The prior step added omalizumab on top of a 2nd generation H1-antihistamine. After reassessment at 6 months, the treatment goals — a continuous UAS7 = 0 and a well-controlled disease state — were not achieved. This failure is the escalation trigger for the next treatment line.
Next-line approach (partial overview)
For patients unresponsive to a 2nd generation H1-antihistamine and omalizumab, the evidence-based next step involves adding an immunosuppressant — ciclosporin — alongside the existing antihistamine. The full dosing regimen, monitoring requirements, and decision algorithm are in the structured protocol.
Treatment goal
Complete symptom control: a continuous UAS7 = 0, a well-controlled disease state, and normalisation of quality of life.
References
DOI: 10.1111/all.15090
- We suggest using ciclosporin for the treatment of patients with CU unresponsive to high dose of 2nd generation H1-antihistamine and omalizumab.
- Patients with urticaria who do not show sufficient benefit from treatment with omalizumab, should be treated with ciclosporin 3.5–5 mg/kg per day.
- The goal of treatment is to treat the disease until it is gone and as efficiently and safely as possible aiming at a continuous UAS7 = 0, complete control and a normalization of quality of life.
View source ↗